November 8, 2017

FDA OKs Batu Biologics’ ValloVax for Clinical Investigation in Certain Solid Tumors

News

The U.S. Food and Drug Administration (FDA) has cleared Batu Biologics to advance its immunotherapy, ValloVax, into clinical trials for certain solid tumors, the company announced. This is the first immunotherapy targeting the blood ... Read more

August 21, 2014August 21, 2014

Batu Biologics Funds Lung Cancer Vaccine with Alternative Crowdfunding Campaign

News

The immunotherapy developer Batu Biologics has successfully raised $100,000, using an alternative fundraising approach for the biotech sector, the Indiegogo crowdfunding platform, to fund the development of the first anti-angiogenic cancer vaccine for ... Read more